Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 76-92 , February 2009

Cancers of the Pancreas and Hepatobiliary System

References 

  1. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008;112:243–249
  2. Billimoria KY, Bentrem DJ, Yo CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227–1233
  3. American Cancer Society. Cancer facts and figures 2008. Atlanta, GA: American Cancer Society.Available at: http://www.cancer.org (accessed August 10, 2008).
  4. National Cancer Institute. Pancreatic cancer: six years of research progress. December 2007. Available at: http://planning.cancer.gov/disease/2007PancreaticProgRpt.pdf (accessed Aug 10, 2008).
  5. Brezden-Masley C, Krezyzanowska M. Pancreatic cancer: review of current management principles. Geriatr Aging. 2005;8:33–38
  6. Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. J Cell Biochem. 2005;95:649–656
  7. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol. 1996;23:241–250
  8. Clark JW. Pancreatic cancer. In:  Chabner BA,  Lynch TJ,  Longo DL editor. Harrison's manual of oncology. New York: McGraw Hill; 2008;p. 402–409
  9. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806
  10. Sauter PK, Coleman J. Pancreatic cancer: a continuum of care. Semin Oncol Nurs. 1999;15:36–47
  11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma.V.1.2008. Available at: www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf (accessed April 4, 2008).
  12. Salles A, Nino-Murcia M, Jeffey RB. CT of pancreas: minimum intensity projections. Abdom Imaging. 2008;33:207–213
  13. Agarwal B, Abu-Hamda E, Molke K, et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in diagnosis of pancreatic cancer. Am J Gastroenterol. 2004;99:844–850
  14. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–2902
  15. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901–1925
  16. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. New York: Springer-Verlag; 2002;
  17. Brown KM, Siripurapu V, Davidson M, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195:318–321
  18. Warshaw AL, Gu ZY, Wittenberg J, et al. Preoperative staging and assessment of respectability of pancreatic cancer. Arch Surg. 1990;125:230–233
  19. Diener M, Heukaeufer C, Schwarzer G, et al. Pancreaticoduodenectomy (class WhippleP versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma (review). Cochrane Review. The Cochrane Library. Hoboken, NJ: John Wiley & Sons; 2008;(Issue 3). pp 1-38
  20. Rocha-Lima CM. New directions in the management of advanced pancreatic cancer: a review. Anti-Cancer Drugs. 2008;19:436–446
  21. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928–937
  22. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcomes and survival. Ann Surg Oncol. 2006;13:1201–1208
  23. Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg. 2008;206:451–457
  24. Allendorf JD, Lauerman M, Bill A, et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg. 2008;12:91–100
  25. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903[Erratum appears in 1986;121:1045]
  26. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas and peri-ampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776–784
  27. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection pancreatic cancer. N Engl J Med. 2004;350:1200–1210
  28. Oettle H, Post S, Neuhaus P, et al. Adjuvant with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–272
  29. Regine WF, Winter KW, Abrams R, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–1026
  30. Neoptolemos JP. Clinical evidence does not support the use of adjuvant radiotherapy in pancreatic cancer (editorial). Nature Clin Pract Oncol. 2008;5:431
  31. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–331
  32. Van Laethem J, Van Cutsem E, Hammel P, et al. Adjuvant chemotherapy alone versus chemoradiation after curative resection for pancreatic cancer: feasibility results of a randomised EORTC/FFCD/ GERCOR phase II/III study (40013/22012/0304). [abstr 4514] J Clin Oncol. 2008;26:
  33. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413
  34. Poplin E, Levy DE, Berlin JD, et al. Phase III trial of gemcitabine (30 minute infusion) versus gemcitabine (fixed dose rate infusion) versus gemcitabine + oxaliplatin in patients with advanced pancreatic cancer (E6201). [abstr LBA4004] J Clin Oncol. 2006;(18S):24
  35. Tempero M, Plunkett W, Ruiz V, et al. Randomized phase II compassion of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402–3408
  36. Cunningham D, Chau I, Stocken C, et al. Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. European Cancer Conference (ECCO 13). [abstr PS11] Eur J Cancer Suppl. 2005;3:4
  37. Heinemann V, Labiancia R, Henke A, et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials. Ann Oncol. 2007;18:1652–1659
  38. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966
  39. Ychou M, Desseigne M, Guimbaud R, et al. Randomized phase II trial comparing folfirinox (5FU/leucovorin[LV], irinotecan [I], and oxaliplatin[O] vs. gemcitabine (G) as first line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD II trial. [abstr 4516] Proc Am Soc Clin Oncol. 2007;25:18s
  40. Burtness BA, Powell M, Berlin J, et al. Eastern Cooperative Oncology Group phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomized between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to epidermal growth factor receptor (EGFR): Eastern Cooperative Oncology. [abstr 4519] Proc Am Soc Clin Oncol. 2007;25:18s
  41. Posner M, Chang KJ, Rosemurgy A, et al. Multi-center phase II/III randomized controlled clinical trial using TNFerade combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC). [abstr 4518] Proc Am Soc Clin Oncol. 2007;25:18s
  42. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Hepatobiliary Cancers.V.2.2008. Available at: www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf (accessed July 22, 2008).
  43. Zhu AX. Hepatocellular carcinoma. In:  Chabner BA,  Lynch TJ,  Longo DL editor. Harrison's manual of oncology. New York: McGraw Hill; 2008;p. 410–415
  44. Zhu AX. Cholangiocarcinoma and gallbladder cancers. In:  Chabner BA,  Lynch TH,  Longo DL editor. Harrison's manual of oncology. New York: McGraw Hill; 2008;p. 416–422
  45. McCracken M, Olsen M, Chen MS, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean and Japanese ethnicities. CA Cancer J Clin. 2007;57:190–205
  46. Bartlett DL, Carr BI, Marsh JW. Cancer of the liver. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005;p. 986–1008
  47. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl 1):S72–S78
  48. Cahill BA, Braccia D. Current treatment of hepatocellular carcinoma. Clin J Oncol Nurs. 2004;8:393–399
  49. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI steering committee hepatobiliary task force and the advent of effective drug therapy. The Oncologist. 2007;12:1425–1432
  50. Llovet JM, Ricci C, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390
  51. Choi M, Philip AP. Liver-directed therapies for hepatocellular cancer. Commun Oncol. 2007;4:571–574
  52. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130–1137
  53. Livaraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441–451
  54. Higgins H, Berger D. RFA for liver tumors: does it really work?. Oncologist. 2006;11:801–808
  55. Curley SA, Izzo F. Radiofrequency ablation of primary and metastatic hepatic malignancies. Int J Clin Oncol. 2002;7:72–81
  56. Xu KC, Niu LZ, He WB, et al. Percutaneous cryosurgery for the treatment for hepatic colorectal metastases. World J Gastroenterol. 2008;14:1430–1436
  57. Pawlik T, Schulick R, Choti M. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13:51–64
  58. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–259
  59. Garden OJ, Rees M, Poston GJ, et al. Guidelines for resection of colorectal cancer liver metastases. Gut. 2006;55(Suppl 3):1–8
  60. Kemeny NE, Niedzwiecke D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395–1405
  61. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: appropriate study. Ann Surg. 2004;240:900–909
  62. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  63. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96:896–902
  64. Sotiropoulos GC, Lang H, Frilling A, et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology. 2006;53:322–329
  65. Currin J, Meister EA. A hospital-based intervention using massage to reduce distress among oncology patients. Cancer Nurs. 2008;31:214–221
  66. Gervais DA, Fernandez-del Castillo C, O'Neill MJ, et al. Complications after pancreatoduodenectomy: Imaging and Imaging-guided interventional procedures. Radiographics. 2001;21:673–690
  67. Coleman J. Pancreatic cancer. In:  Yarbro CH,  Frogge MH,  Goodman M editor. Cancer nursing: principles and practices. 6th ed. Sudbury, MA: Jones and Bartlett; 2005;p. 1523–1551
  68. Dunphy EP. Pancreatic cancer: a review and update. Clin J Oncol Nurs. 2008;12:735–741
  69. Lee HS, Kim JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer. 1997;79:2087–2094
  70. Sun VC, Sarna L. Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs. 2008;12:759–766
  71. Sun V, Ferrell B, Juarez G, et al. Symptoms concern and quality of life in hepatobiliary cancers. Oncol Nurs Forum. 2008;35:E45–E52http://ons.metapress.com/content/126n4436x866713/fulltext.pdf
  72. Reyes-Gibby CC, Chan W, Abbruzzese JL, et al. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage. 2007;34:244–252
  73. Griffie J, Mckinnan S, Berry P, et al. Pain. In:  Kuebler KK,  Berry PH,  Heidreich DE editor. End of life care: Clinical practice guidelines. Philadelphia PA: Saunders; 2002;p. 345–382
  74. Fine PG, Miaskowski C, Paice JA. Meeting the challenges in cancer pain management. J Support Oncol. 2004;2:5–22
  75. Wong GY, Schroeder DR, Cains PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer. JAMA. 2004;291:1092–1099
  76. Steel JL, Geller DA, Gamblin TC, et al. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol. 2007;25:2397–2405
  77. Zabora JR. Screening procedures for psychosocial distress. In:  Holland JC editors. Psycho-oncology. New York: Oxford University Press; 1998;p. 653–661
  78. Kelson DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol. 1995;13:748–755
  79. Woods SW, Tesar GE, Murry GB, et al. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiat. 1986;47:12–15
  80. Kuebler KK. Depression. In:  Kuebler KK,  Berry PH,  Heidreich DE editor. End of life care: Clinical practice guidelines. Philadelphia, PA: Saunders; 2002;p. 269–279

PII: S0749-2081(08)00077-6

doi: 10.1016/j.soncn.2008.10.006

Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 76-92 , February 2009

Article Tools